Study Of Abraxane® And Carboplatin As First-Line Treatment For Triple Negative Metastatic Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01207102
Recruitment Status : Terminated (Low enrollment and there is insufficient data to publish.)
First Posted : September 22, 2010
Results First Posted : December 15, 2014
Last Update Posted : December 15, 2014
Celgene Corporation
Information provided by (Responsible Party):
Duke University

Brief Summary:
Taxanes (such as paclitaxel) are highly active to treat breast cancer. Abraxane® (nanoparticle albumin-bound paclitaxel) compared to standard paclitaxel improves efficacy and tolerability. When combined with a taxane, platinum agents improve response in metastatic breast cancer, with carboplatin conferring less toxicity than cisplatin. The investigators hypothesize that the combination of weekly Abraxane® and carboplatin will lengthen time to progression without producing intolerable toxicity.

Condition or disease Intervention/treatment Phase
Metastatic Breast Cancer Drug: Abraxane Drug: Carboplatin Phase 2

Detailed Description:

Paclitaxel and cisplatin are well-recognized for their activity in treating a variety of tumors including breast cancer. As cytotoxins, they have been studied alone and in combination with other chemotherapeutic agents, and have been incorporated into treatment regimens for women who fail previous anthracycline-based therapies. Although both agents are notable for favorable response rates, they are also associated with a variety of adverse events, some of which may be dose-limiting and having a negative effect on quality of life: myelosuppression, nausea and vomiting, diarrhea, stomatitis/mucositis, short- and long-term neuropathy, nephrotoxicity, alopecia and hypersensitivity reactions.

As second-generation compounds, Abraxane® and carboplatin have been shown to improve response rates and may mediate some of the toxicities associated with paclitaxel and cisplatin, respectively. Of particular interest is Abraxane's potential to reduce allergic reactions associated with other taxanes.

This study combines these two agents: primarily, to evaluate progression-free survival; and secondarily, to assess the feasibility and tolerability of this regimen to treat poor prognosis metastatic breast cancer patients.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Study of Abraxane® and Carboplatin as First-line Treatment for "Triple Negative" (Demonstrating no Expression for Estrogen, Progesterone, or Human Epidermal Growth Factor Receptor 2 (HER2)Receptors) Metastatic Breast Cancer
Study Start Date : August 2011
Actual Primary Completion Date : June 2014
Actual Study Completion Date : June 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: Abraxane, Carboplatin
Abraxane 100mg/m2 IV days 1, 8 and 15 of a 28 day cycle Carboplatin area under the concentration curve, (AUC)2 IV days 1,8, and 15 of a 28 day Cycle
Drug: Abraxane
Abraxane® 100 mg/m2 IV over 30 min days 1,8,15 every 28 days
Other Name: paclitaxel protein-bound particles for injectable suspension

Drug: Carboplatin
area under curve(AUC)=2 over 15 minutes days 1,8,15 every 28 days
Other Name: Paraplatin

Primary Outcome Measures :
  1. PFS [ Time Frame: PFS is defined as the interval from study registration to disease progression or death due to any cause, whichever comes first ]
    The primary objective of the trial is to statistically test whether Abraxane® and carboplatin can improve progression-free survival (PFS) as compared to historical controls.

Secondary Outcome Measures :
  1. To Assess the Safety and Tolerability of a Combination Regimen of Weekly Abraxane® and Carboplatin to Treat Women With "Triple Negative" Stage IV Metastatic Breast Cancer [ Time Frame: 2 years ]
    The proportion of patients experiencing any neurotoxicity will be tabulated by grade. The proportion of patients experiencing ≥ grade 3 non-hematologic toxicities (excluding neurotoxicity) and the proportion of patients experiencing ≥ grade 3 hematologic toxicities will be calculated with their exact 80% confidence intervals.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with histologically or cytologically confirmed diagnosis of metastatic (Stage IV) breast cancer;
  • Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST);
  • "Triple negative" disease defined as "tumor demonstrating no expression for estrogen, progesterone or HER2 receptors." (No expression is categorized as ≤ 10% of cells staining or Allred ≤ 2);
  • Aged 18 years or older;
  • Eastern Cooperative Oncology Group (ECOG)ECOG/Zubrod performance status of 0 or 1; life expectancy ≥ 3 months;
  • No prior chemotherapy for metastatic disease.
  • At least 6 months must have elapsed since prior adjuvant chemotherapy.
  • Laboratory tests performed within 14 days of study entry showing:

    • Granulocytes ≥ 1,500/µL;
    • Platelets ≥ 100,000/µL;
    • Hemoglobin ≥ 9.0 gm/dL;
    • Total bilirubin ≤ institutional upper limit of normal (ULN);
    • Aspartate transaminase (AST) and alanine aminotransferase (ALT) ≤ 2.5 times ULN;
    • Alkaline phosphatase ≤ 5 times ULN;
    • Estimated creatinine clearance ≥ 60 mL/min.
    • Urine protein:creatinine ratio ≤ 1.0. or 24 hour urine protein collection demonstrating ≤ 1 gram of protein per 24 hours to be eligible.
  • left ventricular ejection fraction (LVEF) ≥ 50% by multiple gated acquisition scan (MUGA)/Echocardiogram;
  • Informed consent to receive protocol treatment:
  • Cognitive and communication skills adequate to comply with study and/or follow-up procedures;
  • Geographic proximity and ability to comply with weekly study visits for the duration of the treatment;
  • No reproductive potential:

    • If pre-menopausal - Negative serum pregnancy test within 3 days prior to initiation of protocol-based treatment and patient agrees to use contraceptive method (abstinence, intrauterine device, barrier device with spermicide or surgical sterilization) during and for 3 months after completion of protocol treatment;
    • If post-menopausal - Amenorrhea for ≥ 12 months or follicle stimulating hormone (FSH) within post menopausal range.

Exclusion Criteria:

  • Pregnant or breast feeding.
  • Prior treatment with Abraxane® or carboplatin.
  • Prior chemotherapy for metastatic breast cancer.
  • Known hypersensitivity to any component of any study drug.
  • Active infection.
  • Current neuropathy ≥ grade 2.
  • central nervous system (CNS) metastases as determined by head CT with contrast or head MRI.
  • Uncontrolled congestive heart failure (CHF), or history of myocardial ischemia (MI), unstable angina, stroke, or transient ischemia within previous 6 months.
  • Uncontrolled serious contraindicated medical condition or illness.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01207102

United States, North Carolina
Duke University Medical Center
Durham, North Carolina, United States, 27710
Peking University School of Oncology/Beijing Cancer Hospital
Beijing, China, 100142
Sponsors and Collaborators
Duke University
Celgene Corporation
Study Chair: Kimberly L Blackwell, MD Duke University

Responsible Party: Duke University Identifier: NCT01207102     History of Changes
Other Study ID Numbers: Pro00019321
First Posted: September 22, 2010    Key Record Dates
Results First Posted: December 15, 2014
Last Update Posted: December 15, 2014
Last Verified: August 2014

Keywords provided by Duke University:
Breast cancer
Triple negative

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Albumin-Bound Paclitaxel
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action